Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients

Bibliography

• Cornely OA, Maertens J, Bresnik M, Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-97
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402
   PubMed Web of Science ®Google Scholar
• Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009;52:197-205
   PubMed Web of Science ®Google Scholar
• Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007;9:189-95
   PubMed Web of Science ®Google Scholar
• Holzheimer RG, Dralle H. Management of mycoses in surgical patients–review of the literature. Eur J Med Res 2002;7:200-26
   PubMedGoogle Scholar
• Marr KA, Carter RA, Boeckh M, Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000;79:250-60
   PubMed Web of Science ®Google Scholar
• Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803; quiz 4-5
   PubMed Web of Science ®Google Scholar
• Martino R, Parody R, Fukuda T, Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006;108:2928-36
   PubMed Web of Science ®Google Scholar
• Cornet M, Fleury L, Maslo C, Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002;51:288-96
   PubMed Web of Science ®Google Scholar
• Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000;31:545-53
   PubMed Web of Science ®Google Scholar
• Olejniczak K, Kasprzak A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases–a review. Med Sci Monit 2008;14:RA179-89
   PubMed Web of Science ®Google Scholar
• Balloy V, Chignard M. The innate immune response to Aspergillus fumigatus. Microbes Infect 2009;11(12):919-27
   Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008;47:1041-50
   PubMed Web of Science ®Google Scholar
• Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008;47:1321-7
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Dromer F, Harrison TS, Lortholary O. Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis 2008;21:596-603
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Rüping MJGT. Current experience in treating invasive zygomycosis with posaconazole. Clin Microb Infect 2009;15(Suppl 5):77-81 Abstract
   Google Scholar
• Krajicek BJ, Thomas CF Jr, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med 2009;30:265-78, vi
   PubMedGoogle Scholar
• Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007;67:1567-601
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63
   PubMed Web of Science ®Google Scholar
• Morris A, Lundgren JD, Masur H, Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-20
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17
   PubMed Web of Science ®Google Scholar
• Husain S, Alexander BD, Munoz P, Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003;37:221-9
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Ribaud P, Herbrecht R, Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006;42:955-63
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-82
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75
   PubMed Web of Science ®Google Scholar
• Gavalda J, Len O, San Juan R, Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005;41:52-9
   PubMed Web of Science ®Google Scholar
• Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003;22:258-66
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48:265-73
   PubMed Web of Science ®Google Scholar
• San Juan R, Aguado JM, Lumbreras C, Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007;7:964-71
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, Mihu CN, Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2009 . Epub ahead of print (doi: 10.1038/bmt.2009.149)
   Google Scholar
• Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14
   PubMed Web of Science ®Google Scholar
• Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999;1:229-36
   PubMedGoogle Scholar
• Ullmann AJ, Lipton JH, Vesole DH, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47
   PubMed Web of Science ®Google Scholar
• Pugliese F, Ruberto F, Cappannoli A, Incidence of fungal infections in a solid organ recipients dedicated intensive care unit. Transplant Proc 2007;39:2005-7
   PubMedGoogle Scholar
• Almirante B, Rodriguez D, Park BJ, Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829-35
   PubMed Web of Science ®Google Scholar
• Lin MY, Carmeli Y, Zumsteg J, Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005;49:4555-60
   PubMed Web of Science ®Google Scholar
• Sandven P, Bevanger L, Digranes A, Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006;44:1977-81
   PubMed Web of Science ®Google Scholar
• Hajjeh RA, Sofair AN, Harrison LH, Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27
   PubMed Web of Science ®Google Scholar
• Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002;40:3489-92
   PubMed Web of Science ®Google Scholar
• Laupland KB, Gregson DB, Church DL, Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005;56:532-7
   PubMed Web of Science ®Google Scholar
• Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995–1999. Emerg Infect Dis 2003;9:985-90
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Marriott DJ, Chen SC, Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis 2009;11:122-7
   PubMed Web of Science ®Google Scholar
• Martino P, Girmenia C, Micozzi A, Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994;13:797-804
   PubMed Web of Science ®Google Scholar
• Wey SB, Mori M, Pfaller MA, Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-53
   PubMed Web of Science ®Google Scholar
• Kao AS, Brandt ME, Pruitt WR, The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999;29:1164-70
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Pfaller MA. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004;25:624-6
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Jarvis WR, Soucie JM, Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33:177-86
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004;23:739-44
   PubMed Web of Science ®Google Scholar
• Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005;43:235-43
   PubMed Web of Science ®Google Scholar
• Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005; 41:(Suppl 6):S389-93
   PubMedGoogle Scholar
• Pelz RK, Hendrix CW, Swoboda SM, Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-8
   PubMed Web of Science ®Google Scholar
• Leon C, Ruiz-Santana S, Saavedra P, A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34:730-7
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Sable C, Sobel J, Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007;26:271-6
   PubMed Web of Science ®Google Scholar
• Pittet D, Monod M, Suter PM, Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8
   PubMed Web of Science ®Google Scholar
• Dupont H, Bourichon A, Paugam-Burtz C, Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003;31:752-7
   PubMed Web of Science ®Google Scholar
• Richet H, Roux P, Des Champs C, Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002;8:405-12
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Biraghi E, Astofi A, European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002;51:297-304
   PubMed Web of Science ®Google Scholar
• Marchetti O, Bille J, Fluckinger U, Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 2004;38:311-20
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44:760-3
   PubMed Web of Science ®Google Scholar
• Colombo AL, Nucci M, Salomao R, High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999;34:281-6
   PubMed Web of Science ®Google Scholar
• Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003;52:71-7
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Lau YJ, Chuang YC, Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005;49:512-17
   PubMed Web of Science ®Google Scholar
• Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat 2008;11:25-31
   PubMed Web of Science ®Google Scholar
• Dictar MO, Maiolo E, Alexander B, Mycoses in the transplanted patient. Med Mycol 2000;38:(Suppl 1):251-8
   PubMedGoogle Scholar
• Linhares MM, Gonzalez AM, Trivino T, Simultaneous pancreas-kidney transplantation: infectious complications and microbiological aspects. Transplant Proc 2004;36:980-1
   PubMedGoogle Scholar
• Lumbreras C, Fernandez I, Velosa J, Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995;20:514-20
   PubMed Web of Science ®Google Scholar
• Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993;16:677-88
   PubMed Web of Science ®Google Scholar
• Shi SH, Lu AW, Shen Y, Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation. Chin Med J (Engl) 2008;121:625-30
   PubMedGoogle Scholar
• Benedetti E, Gruessner AC, Troppmann C, Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg 1996;183:307-16
   PubMedGoogle Scholar
• Husain S, Tollemar J, Dominguez EA, Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003;75:2023-9
   PubMed Web of Science ®Google Scholar
• Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003;9:451-62
   PubMed Web of Science ®Google Scholar
• Naitoh K, Higuchi T, Sasaki H, Rapid diagnosis of donor infection and renal allograft contamination using a polymerase chain reaction technique and rapid shaking culture. Hinyokika Kiyo 2005;51:715-18
   PubMedGoogle Scholar
• Mikaelsson L, Jacobsson G, Andersson R. Pneumocystis pneumonia–a retrospective study 1991–2001 in Gothenburg, Sweden. J Infect 2006;53:260-5
   PubMedGoogle Scholar
• Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13
   PubMed Web of Science ®Google Scholar
• Gordon SM, LaRosa SP, Kalmadi S, Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999;28:240-6
   PubMed Web of Science ®Google Scholar
• Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002–2004. Scand J Infect Dis 2007;39:589-95
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007:CD005590
   PubMedGoogle Scholar
• Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis 2009;48:1566-76
   PubMedGoogle Scholar
• Singh N, Lortholary O, Dromer F, Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 2008;86:647-51
   PubMedGoogle Scholar
• Pagano L, Valentini CG, Posteraro B, Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009;21:322-9
   PubMed Web of Science ®Google Scholar
• Trifilio S, Singhal S, Williams S, Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-6
   PubMed Web of Science ®Google Scholar
• Tong SY, Peleg AY, Yoong J, Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis 2007;9:241-3
   PubMedGoogle Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16
   PubMed Web of Science ®Google Scholar
• Bruggemann RJ, Alffenaar JW, Blijlevens NM, Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441-58
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-30
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27
   PubMed Web of Science ®Google Scholar
• Fleming RV, Kantarjian HM, Husni R, Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82
   PubMed Web of Science ®Google Scholar
• Leroy O, Gangneux JP, Montravers P, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 2009;37:1612-18
   PubMed Web of Science ®Google Scholar
• Hachem R, Hanna H, Kontoyiannis D, The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008;112:2493-9
   PubMed Web of Science ®Google Scholar
• Wingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 2004;39:(Suppl 4):S176-80
   PubMedGoogle Scholar
• Marr KA, Crippa F, Leisenring W, Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Bohme A, Buchheidt D, A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55:445-9
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42
   PubMed Web of Science ®Google Scholar
• Wakiec R, Prasad R, Morschhauser J, Voriconazole and multidrug resistance in Candida albicans. Mycoses 2007;50:109-15
   PubMedGoogle Scholar
• Muller FM, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 2000;46:338-40
   PubMed Web of Science ®Google Scholar
• Glockner A, Steinbach A, Vehreschild JJ, Cornely OA. Treatment of invasive candidiasis with echinocandins. Mycoses 2009;52(6):476-86
   Google Scholar
• Pappas PG, Rotstein CM, Betts RF, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14
   PubMed Web of Science ®Google Scholar
• Vandewoude KH, Blot SI, Depuydt P, Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006;10:R31
   PubMed Web of Science ®Google Scholar
• Copp DH, Godwin JD, Kirby KA, Limaye AP. Clinical and radiologic factors associated with pulmonary nodule etiology in organ transplant recipients. Am J Transplant 2006;6:2759-64
   PubMedGoogle Scholar
• Park YS, Seo JB, Lee YK, Radiologica and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin Radiol 2008;63:673-80
   PubMedGoogle Scholar
• Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-27
   PubMed Web of Science ®Google Scholar
• Husain S, Kwak EJ, Obman A, Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004;4:796-802
   PubMed Web of Science ®Google Scholar
• Husain S, Paterson DL, Studer SM, Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007;83:1330-6
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Jaber RA, Leather HL, Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007;45:1759-65
   PubMed Web of Science ®Google Scholar
• Senn L, Robinson JO, Schmidt S, 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008;46:878-85
   PubMed Web of Science ®Google Scholar
• Akamatsu N, Sugawara Y, Kaneko J, Preemptive treatment of fungal infection based on plasma (1 –> 3)beta-D-glucan levels after liver transplantation. Infection 2007;35:346-51
   PubMed Web of Science ®Google Scholar
• Klingspor L, Loeffler J. Aspergillus PCR formidable challenges and progress. Med Mycol 2009; 47:(Suppl 1):S241-7
   PubMedGoogle Scholar
• Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003;101:3365-72
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006;19:571-6
   PubMed Web of Science ®Google Scholar
• Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:729-37
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Malena M, Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006;12:850-8
   PubMed Web of Science ®Google Scholar
• Husain S, Zaldonis D, Kusne S, Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006;8:213-18
   PubMedGoogle Scholar
• Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008;8:426-31
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Cornely O, Ullmann AJ, An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006;57:317-25
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22-8
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004:CD004291
   PubMedGoogle Scholar
• Husain S, Paterson DL, Studer S, Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006;6:3008-16
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. ASH Annual Meeting Abstracts 2007;110:163
   Google Scholar
• Sole A. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. Int J Antimicrob Agents 2008;32:(Suppl 2):S161-5
   PubMedGoogle Scholar
• Drew RH, Dodds Ashley E, Benjamin DK Jr, Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-7
   PubMed Web of Science ®Google Scholar
• Palmer SM, Drew RH, Whitehouse JD, Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001;72:545-8
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L, Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-8
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL, Gayowski T, Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001;71:910-13
   PubMedGoogle Scholar
• Fortun J, Martin-Davila P, Moreno S, Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003;52:813-19
   PubMed Web of Science ®Google Scholar
• Fortun J, Martin-Davila P, Montejo M, Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009;87:424-35
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Heussel CP, Cornely OA. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002;346:1745-7; discussion 7
   PubMed Web of Science ®Google Scholar
• Marr KA. Empirical antifungal therapy–new options, new tradeoffs. N Engl J Med 2002;346:278-80
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Winston DJ, Bow EJ, Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412-22
   PubMed Web of Science ®Google Scholar
• Salavert M. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients? Int J Antimicrob Agents 2008;32(Suppl 2):S149-53
   PubMedGoogle Scholar
• Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J 1999;13:180-6
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51
   PubMed Web of Science ®Google Scholar
• Silveira FP, Kwak EJ, Paterson DL, Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J Heart Lung Transplant 2008;27:850-5
   PubMedGoogle Scholar
• Maertens J, Theunissen K, Verhoef G, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50
   PubMed Web of Science ®Google Scholar
• Piarroux R, Grenouillet F, Balvay P, Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004;32:2443-9
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H, Caspofungin as first-line therapy of invasive aspergillosis in haematological patients: a study of the EORTC Infectious Diseases Group. TIMM 2007; Turin 2007
   Google Scholar
• Alexander BD, Perfect JR, Daly JS, Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008;86:791-6
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802
   PubMed Web of Science ®Google Scholar
• van't Wout JW, Novakova I, Verhagen CA, The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991;22:45-52
   PubMed Web of Science ®Google Scholar
• Caillot D, Bassaris H, McGeer A, Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-90
   PubMed Web of Science ®Google Scholar
• Denning DW, Lee JY, Hostetler JS, NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006;81:320-6
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L. Combination antifungal therapy: a critical review of the evidence. Clin Microbiol Infect 2008;14:(Suppl 4):65-70
   PubMedGoogle Scholar
• Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Resch G, Nachbaur D, The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007;45:e101-4
   PubMed Web of Science ®Google Scholar
• Rickerts V, Mousset S, Lambrecht E, Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007;44:1078-83
   PubMed Web of Science ®Google Scholar